China SXT Pharma CFO files Form 3

China SXT Pharmaceuticals, Inc. submitted a Form 3 identifying Pan Xiaodong Sean, the company’s Chief Financial Officer, as a reporting person.

Rhea-AI Filing Summary

China SXT Pharmaceuticals, Inc. submitted a Form 3 identifying Pan Xiaodong Sean, the company’s Chief Financial Officer, as a reporting person. The data provided shows no buy, sell, or derivative transactions, with all transaction counts and share amounts reported as zero.

Key Terms

Form 3, Chief Financial Officer, reporting person

3 terms

Form 3 regulatory

"CONTENT METADATA: "form_type": "3""

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Financial Officer financial

""officer_title": "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

reporting person regulatory

""reportingPersons": [ { "name": "Pan Xiaodong Sean""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SXTC Form 3 filing for Pan Xiaodong Sean show?

The Form 3 lists Pan Xiaodong Sean, Chief Financial Officer of China SXT Pharmaceuticals, as a reporting person. In the provided data, all transaction-related counts and share amounts are zero, indicating no reported trades or derivative exercises in this filing.

Were any SXTC shares bought or sold in this Form 3 data?

No, the transaction summary shows zero buyCount, sellCount, buyShares, and sellShares. This means the Form 3 data provided does not report any purchases, sales, or net share changes for China SXT Pharmaceuticals in this instance.

Does the SXTC Form 3 include any derivative transactions?

No, derivativeTransactionCount and exerciseCount are both zero, and derivativeSummary is empty. This indicates no option exercises, conversions, or other derivative transactions were reported for Pan Xiaodong Sean in this Form 3 snapshot.

What is the role of the reporting person in the SXTC Form 3?

The reporting person, Pan Xiaodong Sean, is identified as an officer of China SXT Pharmaceuticals with the title Chief Financial Officer. This establishes him as a senior executive subject to insider reporting requirements in the Form 3 filing data.

Does the SXTC Form 3 mention gifts, tax withholding, or restructuring transactions?

No, the transactionSummary shows giftCount, taxWithholdingCount, and restructuringCount all equal zero. This means there are no reported gifts, tax-withholding dispositions, or restructuring-related transfers associated with Pan Xiaodong Sean in this Form 3 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pan Xiaodong Sean

(Last) (First) (Middle)

ROOM 503, 1ST BUILDING, CHENGSHIZHIGUANG

(Street)

TAIZHOU JIANGSU

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
01/31/2022

3. Issuer Name and Ticker or Trading Symbol
China SXT Pharmaceuticals, Inc. [ SXTC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Xiaodong Pan	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)